PBAC's latest decision on Eslicarbazepine acetate: Recommended with restriction (2021). Considered for Adjunctive therapy for patients aged 16 years and older with partial onset seizures with or without secondary generalisation that are intractable (treatment-resistant) and have failed to be controlled by other anti-epileptic drugs.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2021
Submissions
1
2021 → 2021
Eligible population
Adjunctive therapy for patients aged 16 years and older with partial onset seizures (with or without secondary generalisation) that are intractable and have failed to be controlled satisfactorily by other anti-epileptic drugs (requiring at least one first-line agent and at least two second-line adjunctive agents).
Therapy area
Neurology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
ORR
Key trials
Study 304, SP667, SP754, SP755
Comparator
lacosamide
Economic model
Cost-minimisation
Eligible patients/year
25,700
ICER note
Cost-minimisation analysis submitted; no ICER calculated by design.
Risk sharing
Risk-sharing arrangement in place — A risk-sharing arrangement currently applies to lacosamide, brivaracetam and perampanel for intractable partial onset epileptic seizures.